Article Image

ASH 2020 Study Preview: Dose Escalation of Cael-101 In AL Amyloidosis Patients

Op-Med is a collection of original articles contributed by Doximity members.

A talk with Dr. Jason Valent about ASH abstract 729: Safety, Tolerability, and Efficacy of Cael-101 in AL Amyloidosis Patients Treated on a Phase 2, Open-Label, Dose Selection Study to Evaluate the Safety and Tolerability of Cael-101 in Patients with AL Amyloidosis

What are the highlights that attendees should take away from your presentation?

The takeaway is the safety of CAEL-101 in combination with CyBorD in AL amyloidosis patients along with early organ responses in patients treated with CAEL-101 and CyBorD.

What is the central question that your study and/or presentation tries to answer?

The central question is what is the recommended phase 3 dose of CAEL-101 in combination with CyBorD?

If applicable, what are the key findings from your study?

Key finding is the safety of CAEL-101 in combination with CyBorD in AL amyloidosis patients along with early organ responses in patients treated with CAEL-101 and CyBorD. Phase 3, double blind, placebo-controlled trials have started based on the results of this Phase 2 study.

What else would you like attendees to know about your presentation?

Phase 3, double blind, placebo-controlled trials have started based on the results of this Phase 2 study.

What are 3–5 questions you would ask attendees about the topic of your presentation to spark an engaging conversation? 

- Were there any cardiac arrhythmias seen in these patients?

- Were there any patients that discontinued treatment due to toxicity from CAEL-101?

- What were the PK assessments like in the patients with significant organ responses?

Dr. Valent has received payment for lectures from the Celgene corporation, Takeda pharmaceuticals, and the Amgen corporation.

More from Op-Med